Identifying and avoiding things that trigger symptoms in your individual case can help you to control your condition. Here are three easy ways to start tracking:
Published by the National Rosacea Society.
Editor: Dr. Lynn Drake, Department of Dermatology, Harvard Medical School.
Managing Editor: Andrew Huff.
Rosacea Review is a newsletter published by the National Rosacea Society for people with rosacea. The newsletter covers information pertaining to the disease and its control, including news on research, results of patient surveys, success stories, lifestyle and environmental factors, and tips on managing its signs and symptoms. To receive Rosacea Review by mail, please join the NRS. You can also sign up to receive the newsletter by email.
A new study has documented for the first time the clinical differences between subtype 1 (erythematotelangiectatic) rosacea – characterized by facial redness and, sometimes, visible blood vessels – and a condition with visible blood vessels from sun damage known as telangiectatic photoaging (TP), providing a clear picture of the differences between the two disorders and aiding in appropriate treatment.1
In a recent study funded by the National Rosacea Society, Dr. Yoshikazu Uchida, research dermatologist at the University of California – San Francisco, and colleagues overcame a challenge that may lead to important advances in the treatment of rosacea.
As research continues to reveal the many ways the human microbiome may affect human health, the potential role of Demodex mites in rosacea has come into sharper focus with new technology and may point to new approaches in patient care, according to experts at a roundtable on the clinical implications of Demodex in rosacea.
While it has long been observed that rosacea may tend to run in families, the first genome-wide association study of rosacea may have discovered the genetic variants that are linked to this chronic skin disorder – as well as potential connections between rosacea and certain autoimmune disorders.1